On May 15, 2026, Cormorant Asset Management disclosed a buy of 313,645 shares of Alumis (NASDAQ:ALMS), with the estimated transaction value at $7.84 million based on quarterly average pricing.
What happened According to a May 15, 2026 SEC filing, Cormorant Asset Management increased its position in Alumis by 313,645 shares during the first quarter
The firm’s estimated trade size was $7.84 million, calculated using the quarter’s average closing price. The stake’s value at quarter-end rose by $51.52 million, a figure that incorporates both buying activity and market price movements. What else to know – Cormorant’s buy brings its Alumis stake to 4.37% of 13F assets as of March 31, 2026. – Top holdings after the filing: – NASDAQ:PRAX: $285.30 million (14.4% of AUM) – NASDAQ:BBOT: $160.01 million (8.1% of AUM) – NASDAQ:EYPT: $106.54 million (5.4% of AUM) – NASDAQ:EWTX: $102.69 million (5.2% of AUM) – NASDAQ:ERAS: $93.84 million (4.7% of AUM) – – As of May 14, 2026, Alumis shares were priced at $24.63, up about 400% over the past year and vastly outperforming the S&P 500’s roughly 25% gain in the same period.
Company overview Company snapshot – Alumis develops clinical-stage biopharmaceutical products targeting autoimmune and neuroinflammatory diseases, including ESK-001 and A-005, with a focus on allosteric TYK2 inhibitors. – The company operates a research-driven model, advancing proprietary drug candidates through clinical trials. – It targets healthcare providers and pharmaceutical partners addressing autoimmune and neurodegenerative conditions, with a primary focus on the biotechnology and healthcare sectors. Alumis is a clinical-stage biotechnology company specializing in the development of novel therapies for autoimmune and neuroinflammatory disorders. The company leverages its expertise in allosteric TYK2 inhibition to advance a pipeline of differentiated drug candidates.